Emmanuel Benjamin Walter, MD

Dr. Emmanuel Walter, MD, MPH, Professor of Pediatrics, serves as the Duke Human Vaccine Institute (DHVI) Chief Medical Officer and directs the Duke Vaccine and Trials Unit. In these roles, Dr. Walter provides strategic and operational leadership for clinical research conducted at the Institute. In addition, he provides oversight of regulatory compliance for DHVI clinical research activities.
Dr. Walter has dedicated his career to advancing research and clinical practice in vaccinology, infectious diseases, and child health. He currently serves as the principal investigator for the Duke Clinical Core of the Collaborative Influenza Vaccine Innovations Centers (CIVICs) funded by the National Institute of Allergy and Infectious Diseases (NIAID). The goal of this work is to evaluate promising next generation influenza vaccine candidates in Phase I and Phase I/II clinical trials and human challenge studies. He is the Duke Co-Principal Investigator for the NIAID Vaccine and Treatment Evaluation Unit (VTEU) which conducts clinical trials of vaccines and treatments for infectious diseases. He is also the Duke Principal Investigator for the CDC-funded Clinical Immunization Safety Assessment Project which conducts studies to identify risk factors and preventive strategies for adverse events following immunization, particularly in special populations. Lastly, he is the Principal Investigator for a CDC-funded project to further understand and reduce disparities in vaccine coverage among rural adolescents.
Dr. Walter's focused area of interest include vaccine development, vaccine safety, vaccine coverage, prevention and treatment of infectious diseases.
Education and Training
- M.P.H., University of North Carolina - Chapel Hill, 1992
- M.D., University of Maryland, College Park, 1983
- B.S., University of Notre Dame, 1979
Selected Grants and Awards
- Duke Women's Reproductive Health Research Scholars
- VTEU 14-0053 Task C Option 2 Protocol Implementation
- VTEU: Task Area D: Research Laboratory Analysis Protocol #14-0053
- CISA 10-Pediatric COVID-19 Vaccination (Lead)
- 2020 CISA 04-COVID Maternal Study
- VTEU 14-0053 Task C Option 4 Protocol Implementation
- VTEU Sample Task Orders
- Vaccine and Treatment Evaluation Units (VTEU)
- A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER BLIND, DOSE-FINDING STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND POTENTIAL EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINS
- VTEU Task D Option 1 Protocol FY.2015.A4D14.0033
- VTEU Task D Option 2 Protocol FY.2015.A4D14.0033
- VTEU Task D Option 3 Protocol FY.2015.A4D14.0033
- VTEU Task D Option 4 Protocol FY.2015.A4D14.0033
- CISA 07 Adult RCT COVID-19 Vaccination (Lead)
- CISA 2017 06 - Clinical Consult - Base
- CISA 2017 06 - Clinical Consult - Opt 2
- CISA 2018-2019 - Clinical Consult - Opt 2
- CISA 2018-2019 - Clinical Consult - Base
- CIVICS Component C - Option 13A
- CIVICS Component C - Option 16
- RTOP 2018 CISA 01 Flublok Lead Task 2
- RTOP 2018 CISA 01 Flublok Lead Task 3
- RTOP 2018 CISA 01 Flublok Lead Task 4
- CIVICS Component C - Option 8
- VTEU 14-0053 Task C Option 3 Protocol Implementation
- CISA Shingrix 2020 Lead Site Task 2
- Clinical Vaccine Safety Evaluation - Contributing Site - Task COVID - Optional Task 3
- CISA RFTP Syncope Prevention Study (Lead) 2020-2022
- CISA RTOP 2017-01 Apnea (Lead) - Option 2
- CISA 2020-2021 - Clinical Consult - Opt 2
- CISA 2020-2021 - Clinical Consult - Base
- CIVICS Component C - Option 1
- Lead Site Task 1: Simultaneous RZV and all V4 Vaccination (Lead)
- RTOP 2018 CISA 01 Flublok Lead Base
- RTOP 2018 CISA 01 Flublok Lead Task 1
- CIVICS Component A - Option 1
- Reducing disparities in adolescent HPV vaccination coverage in the Carolinas
- Research Training in Allergy and Clinical Immunology
- Adaptive COVID-19 Treatment Trial (ACTT)
- RFTP 2018 CISA 05 FLUAD Logical Follow On Task 1
- VTEU 18-0010.B1C1.0120_Task C Option 1
- VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Option 1
- VTEU Protocol Implementation Option 1
- Task Area B-D Task Order 16-0058.B1C1D1.0076
- VTEU RTOP FY.2017.B8C12.0080 - Task B
- VTEU Task C Option 2 Protocol 14-0079.B1C1.0028
- CISA RTOP 2017-01 Apnea (Lead) - Option 1
- HVTN 3002 Protocol Funding (PF) - Durham Protocol-Specific Site
- IMPAACT 2021 Core funding PTCL 11
- IMPAACT PTCL 10 MOD 03 PF Y14
- VTEU 13-0053 Task Area C: Phase I, single dose, open-label, parallel group study comparing the pharmacokinetics and safety of PA-824 in subjects with mild, moderate, and severe hepatic impairment to matched, normal, healthy subjects.
- CISA: 2015 CISA 02 - Contributing Site Base Task: Consultation for the LAIV and Asthma Study (Contributing)
- CISA: 2015 CISA 02 - Contributing Site Optional Task 1: Enrollment and Data Collection for the LAIV and Asthma Study (Contributing)
- CISA 2018-2019 - Clinical Consult - Opt 2
- VACCINE AND TREATMENT EVALUATION UNITS (VTEU) PROTOCOL DEVELOPMENT, IMPLEMENTATION AND ASSAYS TASK AREA B-D PHASE 1 PK TRIAL TO EVALUATE FOSFOMYCIN TASK ORDER 16-0058.B1C1D1.0076
- VTEU Task Order 16-0058.B1C1D1.0076 - Task D
- VTEU Task D Protocol FY.2015.D1B1C1.0032
- VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Base
- VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Base-A
- VTEU RTOP FY.2017.B8C12.0080 - Task C - Option 1
- VTEU RTOP FY.2017.B8C12.0080 - Task C - Option 3
- VTEU RTOP FY.2017.B8C12.0080 - Task C - Option 8
- VTEU Task Area D Option 9 Protocol FY.2016.D1.0026
- VTEU Task Area C Option 3 Protocol FY.2016.C1.0026
- VAC057: Assess the reactogenicity, safety, and immunogenicity of a live attenuated universal influenza vaccine
- IMPAACT Trial--13 CF
- CISA RFTP 2017-03 Syncope Prevention Study (Lead) - Option 2
- RFTP 2016 CISA 01 - Base - FLUAD vs. Fluzone® High-Dose Study (Lead)
- VTEU 18-0010.B1C1.0120_Task B Base
- VTEU 14-0053 Task Area A Project Logistics and Site Activation
- VTEU: Task Area C: Protocol Implementation - Option 2 Protocol #14-0053
- VTEU Task Order 18-0011.B1.C1.0116-Task B Base
- VTEU RTOP FY.2019.A1B1C1D1.0103 - Task A - Base
- VTEU Task C Option 1 Protocol 15-0066.B1C1D1.0041
- VTEU Task Area D Option 8B Protocol FY.2016.D1.0026
- VTEU Task B Base Protocol 15-0066.B1C1D1.0041
- IMPAACT trial
- VTEU Task Area D Option 8 Protocol FY.2016.D1.0026
- CISA RFTP 2017-03 Syncope Prevention Study (Lead) - Base
- CISA RFTP 2017-03 Syncope Prevention Study (Lead) - Option 1
- CISA: 2015 CISA 03 - Lead Site Optional Task 1 (Combined Options 1-11): Additional Subjects for Maternal Tdap and IIV Study (Lead)
- CISA: 2015 CISA 03 - Lead Site Base Task: Maternal Tdap and IIV Study (Lead)
- CISA RTOP 2017-01 Apnea (Lead) - Base
- RFTP 2016 CISA 03 - Option 1 - Fever after Simultaneous Vaccination (Lead)
- VTEU Task Area C Option 3B Protocol FY.2016.C1.0026
- VTEU FY.2018.A1B1C1D1.0077 - Task A - Option 1
- VTEU FY.2018.A1B1C1D1.0077 Task Area A - Base
- VTEU Task B Option 2 - FY.2017.A1B1C1D1.0048
- VTEU Task C Option 1 Protocol 14-0079.B1C1.0028
- VTEU Task Order 16-0047 -Task C Option 1
- VTEU Task Order 16-0047.C1.0090
- A Double-Blind, Randomized, Placebo-controlled, Phase 1 Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine, HydroVax-001, in Healthy Adults
- VTEU: Base -Task Area A: Project Logistics and Site Activation Protocol #14-0053
- RFTP 2016 CISA 03 - Base - Fever after simultaneous vaccination (Lead)
- VTEU Task Area B Option 2 Protocol FY.2016.B1.0026
- CISA Clinical Consult TO I - Option 4
- CISA Task Order No. 3 Tdap Safety in Pregnant Women Infant Option Task 1-CLIN0002
- VTEU Task A Option 1 - FY.2017.A1B1C1D1.0048
- VTEU Task A Base - FY.2017.A1B1C1D1.0048
- CISA Task Order No. 3 Tdap Safety in Pregnant Women Infant Option Task 2-CLIN0003
- VTEU Task Area B Option 2 Protocol FY.2016.B1.0026
- VTEU Task B Base Protocol 14-0079.B1C1.0028
- Option Three (3) of Contract No. 200-2012-53663, Task Order 0001
- CISA TO2 Prophylactic Antipyretics Revision 1-A
- CISA TO2 Prophylactic Antipyretics Revision 3-A
- CISA Task Order No. 3 Tdap Safety in Pregnant Women
- VTEU Task A Protocol FY.2015.A4D14.0033
- Subcontract: Comparing Traditional and Participatory Dissemination of a Shared Decision Making Intervention
- CISA TO2 Prophylactic Antipyretics
- VTEU Task Area A, Base Protocol FY.2016.A1.0026
- VTEU: Option 1-Task Area B: Protocol Development Protocol #14-0053
- Phase I CTU Task Area A: Administrative and Overal Clinical Operations Support and Concept Development
- Multiscale Systems Immunology
- VTEU Task Area A - FY.2015.A1.0016 Base
- Clinical Trial Services Agreement with bioCSL to Study the Performance of CSL Trivalent Influenza Vaccine
- VTEU 12-0016: Task Area C: Protocol implementation
- VTEU 13-0053 Task Area B: Phase I, single dose, open-label, parallel group study comparing the pharmacokinetics and safety of PA-824 in subjects with mild, moderate, and severe hepatic impairment to matched, normal, healthy subjects.
- CISA-Task Order 1: Option 1
- CISA
- SAFETY AND IMMUNOGENICITY OF TDAP VACCINE IN HEALTHY PREGNANT WOMEN, SAFETY IN THEIR NEONATES, AND EFFECT OF MATERNAL IMMUNIZATION ON INFANT IMMUNE RESPONSES TO DTAP VACCINE - DMID 05-0048
- Effectiveness of a Vaccination Program in the Community ObGyn Setting
- A randomized double-blind trial on the safety and immunogenicity of inactivated trivalent influenza vaccine in pregnant women.
- Prevention of Influenza in Infants by Immunization of Their Contacts in the Household (PIIITCH study)
- Preschool Vision Screening in Primary Care Settings
- Implementing Research Findings for Practice Improvement
- Epidemiologic Research Studies of AIDS and HIV Infection
- Epidemiologic Research Studies Of Aids And Hiv Infection
- Evaluation Of Perinatal Hiv Prevention In North Carolina